首页> 外文期刊>Journal of Medicinal Chemistry >Identification of Non-Phosphate-Containing Small Molecular Weight Inhibitors of the Tyrosine Kinase p56 Lck SH2 Domain via in Silico Screening against the pY + 3 Binding Site
【24h】

Identification of Non-Phosphate-Containing Small Molecular Weight Inhibitors of the Tyrosine Kinase p56 Lck SH2 Domain via in Silico Screening against the pY + 3 Binding Site

机译:通过对pY + 3结合位点的计算机筛选,鉴定酪氨酸激酶p56 Lck SH2域的非磷酸化的小分子抑制剂。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The protein p56 lymphoid T cell tyrosine kinase (Lck) is predominantly expressed in T lymphocytes where it plays a critical role in T-cell-mediated immune response. Lck participates in phosphotyrosine-dependent protein-protein interactions through its modular binding unit, the Src homology-2 (SH2) domain. Accordingly, virtual screening methods combined with experimental assays were used to identify small molecular weight nonpeptidic compounds that block Lck SH2 domain-dependent interactions. Virtual screening included scoring normalization procedures and postdocking structural clustering that is shown to facilitate the selection of active compounds. By targeting the well-defined hydrophobic binding pocket known to impart specificity on Lck-protein interactions (i.e., pY + 3 site), inhibitors of the Lck SH2 domain were discovered that omit the phosphotyrosine (pY) or related moieties. The 34 out of 196 computationally selected compounds were shown to inhibit Lck SH2 domain association with phosphorylated immunoreceptor tyrosine based activation motifs peptide. Twenty-four of the active compounds were further tested for their ability to modulate biological function. Thirteen of these compounds showed inhibitory activity in mixed lymphocyte culture assay. Flourescence titration experiments on four of these active compounds further verified their binding to the SH2 domain. Because of their simple chemical structures, these small organic compounds have the potential to act as lead compounds for the development of novel immunosuppressant drugs.
机译:蛋白p56淋巴T细胞酪氨酸激酶(Lck)主要在T淋巴细胞中表达,在T细胞介导的免疫反应中起关键作用。 Lck通过其模块化结合单元Src homology-2(SH2)域参与磷酸酪氨酸依赖性蛋白相互作用。因此,使用虚拟筛选方法与实验方法相结合来鉴定可阻断Lck SH2结构域依赖性相互作用的小分子量非肽类化合物。虚拟筛选包括计分归一化程序和对接后结构聚类,这些聚类被证明有助于选择活性化合物。通过靶向已知对Lck-蛋白质相互作用赋予特异性的明确定义的疏水性结合口袋(即pY + 3位点),发现Lck SH2结构域的抑制剂省略了磷酸酪氨酸(pY)或相关部分。 196种经计算选择的化合物中的34种显示抑制Lck SH2结构域与基于磷酸化免疫受体酪氨酸的活化基序肽的缔合。进一步测试了二十四个活性化合物调节生物学功能的能力。这些化合物中的十三种在混合淋巴细胞培养分析中显示出抑制活性。在这些活性化合物中的四种上的荧光滴定实验进一步证实了它们与SH2结构域的结合。由于其简单的化学结构,这些小的有机化合物有可能作为先导化合物开发新型的免疫抑制剂药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号